PharmiWeb.com - Global Pharma News & Resources
02-Aug-2019

EUROPEAN PATENT NOTICE OF ALLOWANCE FOR THERAPEUTIC COMPOUND, VAL301

London, UK., 01 August 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that the European Patent Office (“EPO”) has issued a Patent Notice of Allowance for ValiRx’s pre-clinical therapeutic compound, VAL301, subject to payment of the relevant fees.

The VAL301 compound is derived from ValiRx’s lead compound, VAL201 and its potential therapeutic approach is based on the same mode of action.  VAL301 is currently in late-stage pre-clinical development (announced 17/07/18) as a non-invasive, effective treatment for the non-cancerous, but hugely debilitating gynaecological condition, endometriosis, which is characterised by endometrial-like tissue found outside of the uterine cavity.  The condition represents one of the major causes of female infertility.

The compound has been developed for the treatment of hormone-induced, non-oncological abnormal growth and cell proliferation conditions. These include indications for endometriosis and benign prostatic hyperplasia, for both of which there is substantial global unmet medical need.

This latest European patent allowance provides additional protection for ValiRx and the allowance in another of the world’s populous regions follows on from ValiRx’s earlier receipt last year of a US Patent Grant (announced 17/07/18) and the more recent Patent Allowances covering China and the Russian Federation (announced 31/01/19).

Dr Satu Vainikka, CEO of ValiRx plc, commented: “This is excellent news and I am delighted that the patent portfolio for our lead compounds continues to strengthen, add value and receive further endorsement.

The current list of Patent Grants and Allowances pertaining to the compounds, VAL301 and VAL201, are as follows:

 

Editor Details

  • Company:
    • VALIRX PLC
  • Name:
    • VALIRX PLC
Last Updated: 02-Aug-2019